Recorded fact · drug.label_indication
drug.label_indication for osimertinib-mesylate|non-small-cell-lung-cancer
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact b73f7a1a resolves to.
The record
| Fact id | b73f7a1ac987ed189f5df61d |
|---|---|
| Entity | drug: osimertinib-mesylate|non-small-cell-lung-cancer |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20240925 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 22f8f885ef89bab2bb1d94318840d40c628db40ffd8d945c5946db2dda97e10a.
The value
{
"ingredient": "Osimertinib Mesylate",
"conditionId": "non-small-cell-lung-cancer",
"conditionName": "Non-Small Cell Lung Cancer",
"matchedAlias": "non-small cell lung cancer",
"context": "indication",
"brand": "TAGRISSO",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "5e81b4a7-b971-45e1-9c31-29cea8c87ce7",
"labelEffectiveTime": "20240925",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: f90842e6552279d839ea47fb8b1b9fb0ec14ba41bdd60a73fc8f4ef6ccd852ef.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.